IDEXX Laboratories’ 2026 Q2 Earnings Call: Placement Pacing, Visit Trends, and CAG Growth Signals Clash

Date of Call: Aug 4, 2026

Financials Results

• Revenue: Increased approximately 10% as reported, and 9% organically
• EPS: $4.27 per share, an increase of 18% as reported and 15% on a comparable basis
• Gross Margin: 64%, up approximately 120 basis points on a comparable basis
• Operating Margin: 35% at the quarter, with comparable operating margin gains of 110 basis points for the year

Guidance:

• Full-year 2026 revenue outlook raised to $4,700,000-$4,745,000, a $5M increase at midpoint, net of a $20M operational improvement and a $15M FX headwind.
• Organic revenue growth outlook of 8.5%-9.7%.
• Full-year EPS outlook raised to $14.69-$14.94 per share, a $0.14 per share increase at midpoint.
• Full-year reported operating margin outlook of 32.3%-32.5%.
• Free cash flow conversion outlook raised to 90%-100% of net income.
• Capital spending expected to be approximately $180 million for the full year.

Business Commentary:

Strong Financial Performance:

• IDEXX Laboratories reported a 10% increase in revenue as reported and 9% organically for the second quarter of 2026.
• The growth was supported by over 10% organic growth in CAG Diagnostics reoccurring revenues, with double-digit gains in both the U.S. and international regions, and strong global growth in water and LPD businesses.

CAG Diagnostics Recurring Revenue Growth:

• CAG Diagnostics recurring revenue increased by 10.3% organically, despite a 50 basis point negative impact related to equivalent days.
• Growth was driven by expanded volumes and net price realization, particularly in the U.S. and internationally, with a strong focus on volume gains in international regions.

Innovation and Instrument Placements:

• IDEXX achieved over 5,200 premium instrument placements, including approximately 1,600 IDEXX inVue Dx analyzers, in the second quarter.
• The placements were driven by the successful commercial launch of inVue Dx and its integration into practice workflows, supported by positive customer feedback.

Operating Margin and Profitability:

• Operating margins achieved 35%, up approximately 120 basis points on a comparable basis, with operating profit gains enabling EPS of $4.27 per share.
• Margin expansion was supported by strong recurring revenue growth in VetLab consumables and reference lab volumes, operational productivity, and favorable business mix.

Increased Full-Year Outlook:

• IDEXX increased its full-year revenue outlook to $4,700,000-$4,745,000, reflecting a $5 million increase at midpoint, and raised its EPS outlook to $14.69-$14.94 per share.
• The increases were driven by strong second-quarter performance, CAG Diagnostics recurring revenue expansion, and operational performance improvements.

Sentiment Analysis:

Overall Tone: Positive

• Management described 'excellent financial results,' 'strong execution,' and 'exceptional second quarter.' They noted 'global momentum,' 'double-digit gains,' and increased guidance, citing 'strong recurring revenue growth' and 'favorable product costs.'

Q&A:

• Question from Erin Wright (Morgan Stanley): Concerns about the rollout of FNA and its progress relative to expectations, and how consumables flow through.
  Response: FNA launch is on track, with rollout broadening into Q3 and planned full availability by year-end. Consumable revenue for inVue Dx is within expected range, with upside potential as FNA expands.

• Question from Erin Wright (Morgan Stanley): Breakdown of reference lab growth components and thoughts on sustained pressure in vet office visits.
  Response: Reference lab growth driven by innovation (Cancer Dx, Fecal Dx), strong commercial execution, and customer conversions, including 20% from competitive labs. U.S. same-store visits declined 1.3%, with pressure on discretionary wellness visits.

• Question from Chris Schott (J.P. Morgan): Vet visit trends across practice types and outlook for getting wellness visits back to growth.
  Response: No significant differences across regions or practice types. Focus is on increasing diagnostic frequency within visits; substantial headroom exists as only ~10% of U.S. wellness visits include blood work.

• Question from Jonathan Block (Stifel): Reasons for recent commercial investments and drivers behind strong two-year CAG Dx recurring revenue stack in 2H.
  Response: Investments are focused internationally to develop diagnostics and wellness, with a proven playbook. Strong guidance is supported by product launches (SDMA in CLIPs, Fecal Dx expansion, Cancer Dx panel broadening) and high customer loyalty.

• Question from Ryan Daniels (William Blair): Potential cannibalization of reference lab from SDMA move to Catalyst.
  Response: No cannibalization; SDMA at point-of-care drives overall diagnostics, often for sick pets, while reference labs continue to include SDMA in panels. Testing begets testing across modalities.

• Question from Daniel Clark (Leerink Partners): Second half CAG growth expectations between U.S. and international segments.
  Response: Strong momentum in both regions; international has multiple quarters of double-digit growth, while U.S. growth is constrained by clinical visit challenges but maintains a growing premium on recurring revenue.

• Question from Michael Ryskin (Bank of America): InVue Dx placement variability and bandwidth to launch multiple platforms.
  Response: Placement variability is normal; Q4 is typically stronger. Commercial capacity is comfortable, with a proven model for managing multiple platforms (Catalyst, inVue Dx, Cancer Dx) and targeted investments.

• Question from Daniel Grosslight (Citi): Phasing of incremental investments in 2H and balance between buybacks and M&A.
  Response: Incremental investments will continue in 2H for long-term growth, with some variability in project timing. Excess capital is deployed via share buybacks, while M&A and in-licensing are assessed opportunistically in core areas.

Contradiction Point 1

inVue Dx Placements and Quarterly Pacing

Contradiction on whether placement patterns are normal/variable or indicate underlying strength.

Michael Ryskin (Bank of America) - Michael Ryskin (Bank of America)

2026Q2: There is normal variability in placement timing based on customer readiness... Year-to-date placements are 2,700, putting the company 50% toward the 5,500 full-year goal. - [Andrew Emerson](CFO) & [Michael Erickson](CRO)

Was the increase in inVue Dx placements from Q1 to Q2 (over 1,600) due to normal quarterly lumpiness or related to FNA? - Michael Ryskin (BofA Securities)

2026Q1: We had a very strong Q4 2025, so quarter-to-quarter placements can be choppy based on customer mix... However, market receptivity is very strong, and we have a high degree of confidence in reaching the 5,500 unit target for the year. - [Jay Mazelsky](CRO)

Contradiction Point 2

Outlook for U.S. Clinical Visit Trends

Contradiction on the near-term outlook for U.S. pet visit trends and underlying drivers.

Erin Wright (Morgan Stanley) - Erin Wright (Morgan Stanley)

2026Q2: U.S. same-store clinical visits declined 1.3% in Q2... Economic factors and inflation are affecting consumer spending on pet care. - [Andrew Emerson](CFO)

Can you break down the components driving the reference lab’s double-digit growth and sustained market share gains, and how do you view ongoing pressure on vet office visits in the context of long-term growth, particularly with metrics like the aging pet population? - Michael Ryskin (BofA Securities)

2026Q1: The Q1 clinical visit decline was -1%, which is about a point better than the initial guide. We see positive momentum from the aging pet population... contributing to the outlook. - [Andrew Emerson](CFO) & [Jay Mazelsky](CRO)

Contradiction Point 3

U.S. Clinical Visit Trends and Outlook

Contradiction on the severity and persistence of pressure on vet office visits.

Erin Wright (Morgan Stanley) - Erin Wright (Morgan Stanley)

2026Q2: U.S. same-store clinical visits declined 1.3% in Q2, with pressure on discretionary wellness visits.... The long-term foundation of the pet population remains positive... - [Michael Erickson](CFO) & [Andrew Emerson](CEO)

What are the key drivers behind the reference lab’s double-digit growth and sustained market share gains, and how do you assess the impact of ongoing pressure on vet office visits—particularly in light of the aging pet population—on long-term growth prospects? - Christopher Schott (JPMorgan Chase & Co, Research Division)

2025Q4: The 2% decline in U.S. clinical visits for 2026 is the baseline assumption until there is clear evidence of improvement. - [Jay Mazelsky](CFO)

Contradiction Point 4

CAG Diagnostics Recurring Revenue Growth Trajectory

Contradiction on whether growth momentum is accelerating or facing headwinds.

Jonathan Block (Stifel) - Jonathan Block (Stifel)

2026Q2: The raised guidance reflects strong Q2 performance and continued momentum. Key drivers for the second half include: Strong execution and customer engagement... High customer loyalty... - [Andrew Emerson](CFO)

What drove the improved two-year stack for CAG Diagnostics recurring revenue in 2H 2026—new customer wins or growth from new products? - Jonathan Block (Stifel, Nicolaus & Company, Incorporated, Research Division)

2025Q4: The Q1 guide incorporates a 50 bps days benefit and assumes continued pressure on clinical visits (~2% decline). The full-year guide reflects these headwinds... - [Andrew Emerson](CFO)

Contradiction Point 5

FNA Launch Timeline

Timeline for full FNA availability appears to have shifted.

Erin Wright (Morgan Stanley) - Erin Wright (Morgan Stanley)

2026Q2: The controlled rollout was broadened into Q3, with planned full availability by year-end. - [Michael Erickson](CFO)

Can you discuss the progress of the FNA rollout relative to expectations, its impact on inVue Dx placements, the consumables flow, and potential upside to consumable targets with the broad launch of FNA? - Erin Wilson Wright (Morgan Stanley)

2025Q3: The FNA launch... is on track for later 2025. - [Jay Mazelsky](CFO)